此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

ScAAV9.U1a.hSGSH的I/II/III期基因转移临床试验

2026年9月17日 更新者:Ultragenyx Pharmaceutical Inc

ScAAV9.U1a.hSGSH 治疗粘多糖贮积症 (MPS) IIIA 的 I/II/III 期基因转移临床试验

The main objective of this study is to evaluate the efficacy and safety of UX111 for the treatment of MPS IIIA.

研究概览

详细说明

Open-label, single dose, dose-escalation clinical trial of UX111 (scAAV9.U1a.hSGSH) injected intravenously through a peripheral limb vein. A limited course of prophylactic immunomodulatory (IM) therapy will be administered. At approved sites adjuvant IM therapy may be administered to selected participants. The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.

This study was previously posted by Abeona Therapeutics, Inc and was transferred to Ultragenyx in August 2022.

研究类型

介入性

注册 (估计的)

36

阶段

  • 阶段2
  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • South Australia
      • North Adelaide、South Australia、澳大利亚、5006
        • 完全的
        • Women's and Children's Hospital
    • Ohio
      • Columbus、Ohio、美国、43205
        • 完全的
        • Nationwide Children's Hospital
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15224
        • 完全的
        • Children's Hospital of Pittsburgh
    • Barcelona
      • Barcelona、Barcelona、西班牙、08035
        • 招聘中
        • Vall d'Hebron Barcelona Hospital Campus
        • 首席研究员:
          • Mireia del Toro, MD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Diagnosis of MPS IIIA confirmed by the following methods:

    • No detectable or significantly reduced SGSH enzyme activity by leukocyte assay, and
    • Genomic DNA analysis demonstrating homozygous or compound heterozygous mutations in the SGSH gene (based upon review of documented results from a qualified laboratory, and with confirmation with Medical Monitor)
  • Age:

    • For Cohort 1-3: From birth (participating sites in USA and Australia) OR 6 months (participating sites in Spain) to 2 years of age with no BSITD-III Cognitive Development Quotient (DQ) requirement, or older than 2 years with a BSITD-III Cognitive DQ of 60 or above (participating sites globally).
    • For Cohort 4 (participating sites in Spain): 3 months to ≤ 2 years of age with no BSITD-III Cognitive DQ requirement or > 2 years of age with a BSITD-III Cognitive DQ ≥ 60 (n = up to 6). Up to 2 additional subjects > 2 years and ≤ 5 years of age with a BSITD-III Cognitive DQ < 60 may also be enrolled. •Subjects must be ≥ 6 months of age before UX111 administration. However, subjects may be consented and initiate relevant Screening Procedures and IM treatment < 6 months of age. Refer to Section 8.2 for relevant screening procedures •For children ≤ 24 months chronological age who were born prematurely, defined as born at < 36 weeks gestational age, the corrected gestational age must be used for determining inclusion •The BSITD-III Cognitive DQ is assessed during the onsite Screening visit, for subjects who require it •The age of the child on the date of the Screening BSITD-III assessment is used to determine the requirement for the BSITD-III Cognitive DQ score.
  • Cohort 4 only: Vaccination status based on age according to country-specific guidelines that is up to date 30 days prior to Enrollment as verified by documentation from the subject's primary care physician, and willing to defer vaccines through 6 months after completion of the subject's IM medication, or longer per Principal Investigator (PI) judgment. Emergency use authorization or conditional marketing authorization of coronavirus disease (COVID) vaccines is included unless there is an accepted medical exemption.

Exclusion Criteria:

  • Inability to participate in the clinical evaluation as determined by PI

  • Cohorts 1 to 3 only: Identification of two nonsense or null variants on genetic testing of the SGSH gene (based upon review of documented results from a qualified laboratory, and with confirmation with Medical Monitor)

  • At least one S298P mutation in the SGSH gene (based upon review of documented results from a qualified laboratory, and with confirmation with Medical Monitor)

  • Has evidence of an attenuated phenotype of MPS IIIA, in the judgement of the PI

  • Presence of a concomitant medical condition that precludes lumbar puncture or use of anesthetics

  • Active viral infection based on clinical observations

  • Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer or precludes the child from participating in the protocol assessments and follow up

  • Cohorts 1 to 3 only: Subjects with total anti-AAV9 antibody titers ≥ 1:100 equivalent to a positive screen as determined by ELISA binding assay in serum

  • Cohorts 1-3 only: Subjects with a positive response for the enzyme-linked immunosorbent spot assay (ELISpot) for T-cell responses to AAV9

  • Cohorts 1-3 only: Serology consistent with exposure to human immunodeficiency virus (HIV), or serology consistent with active hepatitis B or C infection, Cohort 4: Current clinically significant infections (including any requiring systemic treatment including, but not limited to, HIV; hepatitis A, B, or C; varicella zosters virus; human T-cell lymphotropic virus type 1 [HTLV-1]; tuberculosis; or COVID-19) that would interfere with participation in the study.

  • Bleeding disorder or any other medical condition or circumstance in which a lumbar puncture (for collection of CSF) is contraindicated according to local institutional policy

  • Visual, hearing, or other impairment sufficient to preclude cooperation with neurodevelopmental testing

  • Uncontrolled seizure disorder

  • Any item (braces, etc.) or circumstance that would exclude the subject from being able to undergo MRI according to local institutional policy

  • Any other situation that precludes the subject from undergoing procedures required in this study

  • Subjects with cardiomyopathy or significant congenital heart abnormalities

  • The presence of significant non-MPS IlIA related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study

  • Cohorts 1-3: Abnormal laboratory values Grade 2 or higher as defined in common terminology criteria for adverse events (CTCAE) v4.03 for gamma-glutamyl transferase (GGT), total bilirubin, creatinine, hemoglobin, white blood cell (WBC) count, platelet count, prothrombin time (PT) and activated partial thromboplastin time (aPTT), Cohort 4: Any of the following abnormal laboratory values from screening assessment:

    • Aspartate aminotransferase (AST), alanine aminotransferase (ALT), GGT, and/or alkaline phosphatase ≥ 2 × upper limit of normal (ULN) and/or total bilirubin > 1.5 × ULN
    • Anemia (hemoglobin < 10 g/dL)
    • Leukopenia or leukocytosis (total WBC count < 3,000/mm3 and > 15,000/mm3 respectively)
    • Abnormal absolute neutrophil count (ANC) of < 1000/mm3
    • Platelet count < 100,000/mm3
    • Coagulopathy (international normalized ratio [INR] > 1.5) or aPTT > 40 seconds
    • Renal impairment, defined as estimated glomerular filtration rate (eGFR) below the lower limit of normal (age and sex appropriate) based on Bedside Schwartz equation
  • Female of childbearing potential who is pregnant or demonstrates a positive urine or bhCG result at screening assessment (if applicable)

  • Cohorts 1-3: Any vaccination with viral attenuated vaccines less than 30 days prior to the scheduled date of treatment (and use of prednisolone)

  • Previous treatment by hematopoietic stem cell transplantation

  • Previous participation in a gene/cell therapy or enzyme replacement therapy (ERT) clinical trial

Cohort 4 only:

  • Known hypersensitivity, that in the judgment of the PI, places the subject at increased risk for adverse effects.
  • Unwilling to avoid consumption of grapefruit juice and the use of strong inhibitors of CYP3A4 and/or P-gp (eg, ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin), strong inducers of CYP3A4 and/or P-gp (eg, rifampin, rifabutin, phenobarbital, carbamazepine, or phenytoin), and St. John's Wort from 30 days prior to Screening through completion of the IM regimen.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort 1 Low Dose

Dose of 0.5 X 10^13 vg/kg

Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.

其他名称:
  • scAAV9.U1a.hSGSH
  • ABO-102
  • 细小病毒

The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.

实验性的:Cohort 2 Mid Dose

Dose of 1 X 10^13 vg/kg

Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.

其他名称:
  • scAAV9.U1a.hSGSH
  • ABO-102
  • 细小病毒

The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.

实验性的:Cohort 3 High Dose

Dose of 3 X 10^13 vg/kg

Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.

其他名称:
  • scAAV9.U1a.hSGSH
  • ABO-102
  • 细小病毒

The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.

实验性的:Cohort 4 High Dose (Spain Only)

Dose of 3 X 10^13 vg/kg

Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.

其他名称:
  • scAAV9.U1a.hSGSH
  • ABO-102
  • 细小病毒

The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Cerebrospinal Fluid (CSF) Heparan Sulfate (HS) (Disaccharide) Exposure
大体时间:Up to Month 24 Visit

Exposure is defined as the time-normalized area under the curve (AUC) of the percentage reduction from baseline.

Up to Month 24 Visit

次要结果测量

结果测量
措施说明
大体时间
CSF HS 相对于基线的变化百分比
大体时间:基线,截至第 24 个月的访问
基线,截至第 24 个月的访问
总皮质体积相对于基线的百分比变化
大体时间:基线,截至第 24 个月的访问
基线,截至第 24 个月的访问
贝利婴幼儿发展量表 - 第三版 (BSITD-III) 随时间变化的认知原始评分
大体时间:截至第 24 个月的访问
截至第 24 个月的访问
BSITD-III 随时间变化的接受性沟通原始分数
大体时间:截至第 24 个月的访问
截至第 24 个月的访问
BSITD-III 表达性沟通随时间变化的原始分数
大体时间:截至第 24 个月的访问
截至第 24 个月的访问
CSF Ganglioside Type 2 (GM2) Exposure
大体时间:Up to Month 24 Visit

Exposure is defined as the time-normalized area under the curve (AUC) of the percentage change from baseline.

Up to Month 24 Visit
CSF Ganglioside Type 3 (GM3) Exposure
大体时间:Up to Month 24 Visit

Exposure is defined as the time-normalized area under the curve (AUC) of the percentage change from baseline.

Up to Month 24 Visit

其他结果措施

结果测量
大体时间
出现治疗中出现的不良事件和治疗中出现的严重不良事件的参与者人数
大体时间:截至第 24 个月的访问
截至第 24 个月的访问

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Medical Director、Ultragenyx Pharmaceutical Inc

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2016年4月25日

初级完成 (估计的)

2029年3月1日

研究完成 (估计的)

2029年3月1日

研究注册日期

首次提交

2016年3月17日

首先提交符合 QC 标准的

2016年3月17日

首次发布 (估计的)

2016年3月23日

研究记录更新

最后更新发布 (实际的)

2026年9月22日

上次提交的符合 QC 标准的更新

2026年9月17日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • ABT-001
  • UX111-CL301 (其他标识符:Ultragenyx Pharmaceutical Inc)
  • 2015-003904-21 (EudraCT编号)
  • 2023-510032-37-00 (克蒂斯)
  • 2023 (美国 NIH 拨款/合同)
  • 2015 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅